Notes for: Angiotensin-Converting Enzyme InhibitorsLast edited [19/12/2011 11:01:30]Last edited [12/08/2013 10:26:04]
1. ACE inhibitors tend to cause potassium retention. To avoid dangerous hyperkalaemia, potassium supplements or potassium-sparing diuretics should not be used routinely with ACE inhibitors.
2. Renal function should be monitored before initiating treatment with an ACE inhibitor then after one week and whenever dosage is increased. Patients receiving high dose diuretic therapy, with relative hypotension or with known renal impairment should undergo more frequent monitoring (eg an additional check one month and then three months after treatment is started). All patients should undergo an annual check.
3. Lisinopril and ramipril are included as first line ACE inhibitors. They are supported by published studies showing reduced mortality in, for example, heart failure and hypertension.
4. Perindopril is included where a very long duration of action is required. Perindopril should be prescribed generically. Coversyl Arginine® is not dose equivalent and is not included in the formulary.